Status:
COMPLETED
Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis
Lead Sponsor:
Novartis
Conditions:
Osteoporosis
Eligibility:
FEMALE
55-90 years
Phase:
PHASE3
Brief Summary
The aim of this study was to examine the effect of zoledronic acid and alendronate on bone metabolism as measured by biomarkers in postmenopausal women with osteoporosis.
Eligibility Criteria
Inclusion
- \- Low bone mineral density (as indicated by a "t-score" of -2.0 or lower) postmenopausal women
Exclusion
- \- Previous use of oral and iv bisphosphonates, parathormone, strontium ranelate, sodium fluoride.
- Other protocol-defined inclusion/exclusion criteria applied to the study.
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
604 Patients enrolled
Trial Details
Trial ID
NCT00404820
Start Date
October 1 2006
End Date
December 1 2008
Last Update
July 1 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For site information contact Novartis Pharmaceuticals
Multiple Cities, Germany